Nkarta, Inc. Files 2024 10-K Annual Report

Ticker: NKTX · Form: 10-K · Filed: Mar 26, 2025 · CIK: 1787400

Nkarta, INC. 10-K Filing Summary
FieldDetail
CompanyNkarta, INC. (NKTX)
Form Type10-K
Filed DateMar 26, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Nkarta's 2024 10-K is in. Full financials and biz ops details for the year ending Dec 31, 2024.

AI Summary

Nkarta, Inc. filed its 2024 10-K on March 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is based in South San Francisco, California. Key financial data and operational details for the fiscal year are presented in this annual report.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Nkarta, Inc.'s financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Nkarta faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Nkarta, Inc.'s Standard Industrial Classification code?

Nkarta, Inc.'s Standard Industrial Classification code is PHARMACEUTICAL PREPARATIONS [2834].

When did Nkarta, Inc. file its 10-K for the fiscal year ending December 31, 2024?

Nkarta, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 26, 2025.

Where is Nkarta, Inc. located?

Nkarta, Inc.'s business and mail address is 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA 94080.

What is the SEC file number for Nkarta, Inc.'s 10-K filing?

The SEC file number for Nkarta, Inc.'s 10-K filing is 001-39370.

What is the fiscal year end for Nkarta, Inc. as reported in this 10-K?

The fiscal year end for Nkarta, Inc. as reported in this 10-K is December 31.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 26, 2025 regarding Nkarta, Inc. (NKTX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing